2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1846

Increased CD38hiCD27+ Plasmablast Frequency in Remission Predicts Relapsing Disease in Granulomatosis with Polyangiitis Patients
Abstract Number: 2691

Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis
Abstract Number: 2448

Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice
Abstract Number: 1733

Increased Differentiation Resistance of Regulatory T Cells to Endoplasmic Reticulum Stress in Systemic Lupus Erythematosus Patients
Abstract Number: 903

Increased Expression of CCN4/WISP1 in Osteoarthritic Articular Cartilage Is Epigenetically Regulated and Disrupts Cartilage Homeostasis
Abstract Number: 2915

Increased Expression of Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti-Maa Antibody in Rheumatoid Arthritis-Interstitial Lung Disease
Abstract Number: 761

Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis
Abstract Number: 488

Increased Expression of TNF-α and PAD-2 in Human Monocytes Following Treatment with Protein Modified with Malondialdehyde-Acetaldehyde (MAA) and Citrulline
Abstract Number: 18

Increased Frequency of Nailfold Videocapillaroscopy Abnormalities in Primaryantiphospolipid (PAPS) Patients
Abstract Number: 1160

Increased Incidence of Upper and Lower Gastrointestinal Events in Patients with Sarcoidosis: A Population-Based Cohort Study
Abstract Number: 1667

Increased Levels of BAFF in SLE Patients Correlates with Neutrophil Activation and Autoantibody Production
Abstract Number: 766

Increased Plasma Levels of Hsp90 Are Associated with More Severe Organ Involvement in Patients with Systemic Sclerosis
Abstract Number: 2527

Increased Prevalence of Subclinical Atherosclerosis in Moderate-Severe Plaque Psoriasis Patients
Abstract Number: 1766

Increased Renal Damage in Hypocomplementemic Patients with ANCA- Associated Vasculitis
Abstract Number: 2310

Increased Risk of Extreme Obesity in Adults with History of Childhood Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].